SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer. “We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase 1 study of R ...

Latest data shows the largest indicative borrow rate increases among liquid option names include: Starfighters Space, Inc. (FJET) 105.13% +2.83, GraniteShares 1.5x Long COIN Daily ETF (CONL) 11.48% +0.83, Icici Bank (IBN) 1.10% +0.80, EETH ETF (EETH) 19.93% +0.59, Tradr 2X Long IREN Daily ETF (IREX) 24.34% +0.56, iShares Investment Grade Corporate Bond ETF (LQD) 3.00% +0.55, Beyond Meat (BYND) 12.97% +0.49, Rani Therapeutics Holdings (RANI) 18.04% +0.44, Direxion Daily 20 plus Year Treasury Bear 3X Shares ...

Core Insights - Rani Therapeutics has initiated a Phase 1 clinical trial for RT-114, an orally administered GLP-1/GLP-2 dual agonist, PG-102, aimed at treating obesity [1][4] - The trial will assess safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics of RT-114 [1] - ProGen Co., Ltd. is developing PG-102, which has shown glucose-lowering effects and early weight-loss signals in preclinical and clinical data [2] Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company focused on oral delivery of biologics and drugs, utilizing the RaniPill® capsule technology [5] - The RaniPill® capsule is designed to replace subcutaneous injections or intravenous infusions with oral dosing [5] Collaboration Details - RT-114 is developed under a Collaboration Agreement between Rani and ProGen, established in June 2024, sharing development costs and profits equally [6] - Rani will lead the development of RT-114 through Phase 1 trials and will take charge of commercialization in the U.S., Canada, Europe, and Australia after the first Phase 2 trial [6]

Core Insights - Rani Therapeutics is participating in the Evercore Healthcare Conference on December 3, 2025, with CEO Talat Imran and CFO Svai Sanford presenting [1] - The company focuses on oral delivery of biologics and drugs, aiming to replace traditional injection methods with its proprietary RaniPill capsule technology [2] Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company dedicated to advancing technologies for orally administered biologics and drugs [2] - The RaniPill capsule is a novel, proprietary, and patented platform technology designed to facilitate oral dosing instead of subcutaneous or intravenous methods [2] - The company has successfully conducted multiple preclinical and clinical studies to assess the safety, tolerability, and bioavailability of the RaniPill capsule technology [2]

Financial Performance - For the three months ended September 30, 2025, net loss was $7,914,000 compared to $12,722,000 for the same period in 2024, representing a 37% improvement[17]. - The net loss attributable to Rani Therapeutics Holdings, Inc. for the nine months ended September 30, 2025, was $19,368,000, compared to $21,071,000 in 2024, a decrease of 8%[17]. - For the nine months ended September 30, 2025, the company reported a net loss of $31.9 million, compared to a net loss of $40.9 million for the same period in 2024, representing a 22.4% improvement[27]. - The company reported a net loss of $(12,738) million for the quarter ending March 31, 2025, with accumulated deficit reaching $(110,171) million[21]. - The company reported a net loss per Class A common share of $(0.50) for the nine months ended September 30, 2025, compared to $(0.78) for the same period in 2024[102]. Revenue and Contractual Agreements - The company reported no contract revenue for the three months ended September 30, 2025, consistent with the same period in 2024[17]. - The company recognized $0.2 million in contract revenue for evaluation services performed for Chugai Pharmaceutical Co., Ltd. during the nine months ended September 30, 2025[49]. - The company expects to receive a $10.0 million upfront payment from Chugai under a Collaboration and License Agreement, with potential additional milestone payments totaling up to $175.0 million[152]. Expenses and Cost Management - Research and development expenses for the nine months ended September 30, 2025, were $15,296,000, down 23% from $19,872,000 in 2024[17]. - General and administrative expenses decreased to $14,651,000 for the nine months ended September 30, 2025, from $18,484,000 in 2024, a reduction of 21%[17]. - For the three months ended September 30, 2025, total operating expenses decreased by 38.5% to $7.3 million from $11.8 million in 2024[138]. - Research and development expenses for the three months ended September 30, 2025, decreased by 47.8% to $3.2 million from $6.2 million in 2024, primarily due to a $2.4 million reduction in compensation costs[139]. Cash Flow and Liquidity - Cash flows from operating activities showed a net cash used of $19.0 million for the nine months ended September 30, 2025, down from $26.8 million in 2024, indicating a 29.0% reduction in cash outflow[27]. - The company had cash, cash equivalents, and restricted cash equivalents totaling $4.6 million as of September 30, 2025, compared to $4.8 million at the end of the same period in 2024[41]. - The company generated net cash provided by investing activities of $23.9 million for the nine months ended September 30, 2025, compared to $17.3 million in 2024, reflecting a 38.5% increase[27]. - As of September 30, 2025, total cash equivalents and restricted cash equivalents amounted to $2,823,000, up from $904,000 as of December 31, 2024, indicating a significant increase[45]. Stock and Equity - The weighted-average Class A common shares outstanding increased to 46,444 for the three months ended September 30, 2025, from 28,836 in 2024[17]. - The total stockholders' equity attributable to Rani Therapeutics Holdings, Inc. showed a deficit of $7,860,000 as of September 30, 2025, compared to a positive equity of $1,992,000 as of December 31, 2024[15]. - The Company issued 4,354,000 shares of Class A common stock and pre-funded warrants for total gross proceeds of $3.0 million in July 2025[73]. - The Company raised approximately $60.3 million in a private placement, including the conversion of $6.0 million in loans into 12,500,000 shares of Class A Common Stock[123][125]. Strategic Initiatives and Future Plans - The company continues to focus on advancing its product candidates and expanding its technology platform, with ongoing clinical trials planned[10]. - The company plans to initiate a Phase 1 trial for RT-114, an oral anti-obesity therapy, by the end of 2025[129]. - The RaniPill HC is expected to enable delivery of drug payloads up to 200µL in liquid form, with clinical testing planned to start by the end of 2025[115]. - The company is evaluating strategic financing opportunities, including future equity offerings and collaboration agreements, to support its operations moving forward[33]. Financial Obligations and Liabilities - The effective interest rate on the Company's loans was 14.60% as of September 30, 2025, with total principal payments due of $13.75 million[97]. - The total operating lease liability was $4,017,000, with a current portion of $1,049,000[72]. - The minimum annual rental payments under operating lease agreements total $4,770,000, excluding short-term leases[72]. - The company has not recorded a liability under the Tax Receivable Agreement (TRA) as it is not probable that it will realize tax benefits, with potential TRA payable ranging from $0 to $23.4 million[94].

Financial Performance - The company completed a $60.3 million oversubscribed private placement, reducing total debt obligations and enhancing financial stability [5]. - Cash, cash equivalents, and marketable securities as of September 30, 2025, totaled $4.1 million, down from $27.6 million at the end of 2024, but expected to fund operations into 2028 [10]. - Net loss for Q3 2025 was $7.9 million, compared to $12.7 million for the same period in 2024, reflecting improved financial performance [10]. - Total liabilities as of September 30, 2025, were $22.1 million, down from $33.1 million at the end of 2024, indicating improved financial health [14]. Research and Development - Research and development expenses for Q3 2025 were $3.2 million, a decrease of $3.0 million compared to $6.2 million in Q3 2024 [10]. - The company plans to initiate a Phase 1 clinical trial for RT-114, a novel oral therapy targeting obesity, by the end of 2025 [7]. - Preclinical data presented at ObesityWeek® 2025 showed that oral semaglutide delivered via RaniPill® demonstrated comparable bioavailability and weight loss to subcutaneous administration [6]. Corporate Governance - Abraham Bassan and Vasudev Bailey, Ph.D., were appointed to the Board of Directors, enhancing the company's governance [5]. Collaboration and Licensing - Rani Therapeutics entered into a collaboration and license agreement with Chugai Pharmaceutical Co. valued at up to $1.085 billion to develop an oral therapy [5]. Operating Expenses - General and administrative expenses for Q3 2025 were $4.0 million, down from $5.6 million in Q3 2024, primarily due to lower compensation costs [10].

Core Insights - Rani Therapeutics has announced a collaboration with Chugai Pharmaceutical Co. valued at up to $1.085 billion for the development of multiple high-value therapeutics [1][6] - The company completed a $60.3 million oversubscribed private placement led by Samsara BioCapital, indicating strong investor confidence [1][6] - Rani Therapeutics appointed two new members, Abraham Bassan and Vasudev Bailey, Ph.D., to its Board of Directors, enhancing its leadership team [1][6] - The company's cash runway is expected to extend into 2028, providing a solid financial foundation for future operations [1][10] Collaboration and Financial Highlights - The collaboration with Chugai includes an option for Chugai to expand its rights to up to five additional drug targets, potentially increasing the total deal value [6] - The private placement involved institutional investors and included the conversion of $6.0 million of outstanding debt, reducing the company's total debt obligations [6][10] - Rani Therapeutics presented preclinical data on semaglutide delivered orally via the RaniPill® at ObesityWeek® 2025, showcasing the platform's effectiveness [6] Upcoming Milestones - The company plans to initiate a Phase 1 clinical trial for RT-114, a novel oral therapy targeting obesity, by the end of 2025 [4][2] - The upcoming trial will assess safety, tolerability, and pharmacokinetics, which are critical for future development phases [4] Financial Performance - For Q3 2025, Rani Therapeutics reported a net loss of $7.9 million, a decrease from $12.7 million in Q3 2024, reflecting improved financial management [10][14] - Research and development expenses for Q3 2025 were $3.2 million, down from $6.2 million in the same period last year, indicating cost control measures [10][14] - General and administrative expenses also decreased to $4.0 million from $5.6 million year-over-year, further demonstrating financial discipline [10][14]

Group 1: AMTD Digital Inc. - AMTD Digital Inc. (NYSE:HKD) leads the market with a 93.49% price increase to $3.27, driven by a trading volume of approximately 286.36 million [1][6] - The surge in stock price is supported by a remarkable 1,085.9% revenue increase for the six months ending April 30, 2025, following the consolidation of The Generation Essentials Group as a subsidiary since October 2024 [1][6] Group 2: Beneficient - Beneficient (NASDAQ:BENF) experienced a 57.18% increase in its stock price to $0.87, with a trading volume of over 113.62 million [2][6] - The company has regained compliance with Nasdaq's periodic filing and market value requirements, which may have contributed to heightened investor interest [2] Group 3: Rani Therapeutics Holdings, Inc. - Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) saw a 50.69% increase in its stock price to $2.18, with a trading volume of over 31.48 million [3] - The company is set to present preclinical data on its innovative RaniPill® capsule at ObesityWeek® 2025, potentially fueling investor interest [3] Group 4: YD Bio Limited Warrants - YD Bio Limited Warrants (YDESW) experienced a 47.06% increase in its stock price to $1.5, despite a smaller trading volume of 22,699 [4] - The company's focus on detection and therapeutic technologies has shown promising growth potential, attracting investor attention [4] Group 5: Market Overview - The significant price changes and trading volumes reflect a dynamic market environment, with investors showing keen interest in companies across various sectors [5]

Core Insights - Rani Therapeutics is set to present preclinical data on its RaniPill® capsule at ObesityWeek® 2025, highlighting its oral delivery platform for biologics and drugs [1][2] Group 1: Presentation Details - The presentation will focus on the bioequivalence of oral Semaglutide (RT-116) in dogs compared to subcutaneous injections, demonstrating similar weight loss effects [1] - The session will take place on November 6, 2025, from 2:30 pm to 3:30 pm E.T. at the Georgia World Congress Center, with poster number 647 [1] Group 2: Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company dedicated to developing technologies for orally administered biologics and drugs [2] - The RaniPill® capsule is a proprietary and patented platform technology aimed at replacing subcutaneous injections or intravenous infusions with oral dosing [2] - The company has successfully conducted multiple preclinical and clinical studies to assess the safety, tolerability, and bioavailability of the RaniPill® capsule technology [2]

Core Viewpoint - Rani Therapeutics Holdings Inc. (NASDAQ:RANI) is identified as a promising investment opportunity with significant upside potential, driven by its innovative technology and strategic collaborations [1][2]. Group 1: Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company focused on developing technologies for the oral administration of biologics and drugs, providing an alternative to painful injections in the US [3]. Group 2: Investment Drivers - H.C. Wainwright analyst Brandon Folkes initiated coverage of Rani Therapeutics with a Buy rating and a price target of $11, highlighting three major value drivers: the RaniPill platform technology, a collaboration with Chugai Pharmaceutical for a hemophilia product, and five additional drug targets including RT-114, an oral GLP-1/GLP-2 dual agonist candidate [1][2]. - Maxim raised its price target on Rani Therapeutics from $5 to $10, also maintaining a Buy rating, following the announcement of the licensing deal with Chugai Pharmaceutical and a private placement to raise $60 million [2]. Group 3: Future Outlook - The upcoming data readouts on RT-114 are expected to be the primary catalyst for near-term value creation for Rani Therapeutics' shares [2].